Proving that the vaccine works to regulators, along with short-term safety data, is the first hurdle.
Three priority groups can be identified.
This is a marathon and this is only at the first leg of the race.
With shrinking national budgets, increasing deficits, demands for welfare assistance, and economies which are struggling to recover from month long lock-downs and harsh restrictive measures, investing in the unknown is a difficult decision to make.
Proposals should not come from an angry or frustrated place, and must be evidence-based.